Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab and Lenalidomide + GemOx vs Rituximab + GemOx in R/R DLBCL
NCT06521255Phase 3Recruiting
- Sponsor
- InnoCare Pharma
- Start
- May 2024
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tafasitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by InnoCare Pharma. Started May 2024; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06521255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06521255.